Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

COVID Vaccines Moving To Flu Model: FDA Advisory Committee Will Be Asked To Ratify “Simplified” Annual Strain Selection Process

January 23, 2023

FDA Sticks To Orphan Drug Exclusivity By Indication, Despite Catalyst Ruling; Clarity For Now – But More Litigation Likely

January 23, 2023

Prevision Policy Clips | FDA Responds To Catalyst Ruling At Last: No Change In Orphan Drug Exclusivity Policy Going Forward

January 23, 2023

Cidara/Melinta’s Antifungal Rezafungin Likely To Have Limited Use Indication Only; Ad Comm Told That FDA Does Not Believe Broader Claim For Candidiasis Is Supported By Available Data

January 20, 2023

Prevision Policy Clips | Lilly’s Donanemab For Alzheimer’s Gets CRL For Accelerated Approval, But May Mean Little If Timeline Holds

January 20, 2023

Prevision Policy Clips | MPox Drug Development Draft Guidance Announced By FDA January 19

January 19, 2023

FDA Oncology Dose Optimization Guidance: Randomize Where Feasible, Breakthrough Status Does Not Obviate Obligation To Find Optimal Dose Pre-approval

January 18, 2023

Prevision Policy Clips | RSV Adult Vaccine Race Heats Up: Moderna To Submit BLA To FDA In The First Half Of This Year

January 18, 2023

IRA Impact On Small Molecule Development: MedPAC Member Argues That Part D Redesign, Proposed Part B Reforms May “Cancel Out” Price Negotiation Disincentives

January 17, 2023

The Part D Baseline: MedPAC Will Be Watching For Impact Of Plan Changes On Beneficiary Access And Choices During IRA Implementation Period

January 17, 2023

Prevision Policy Clips | FDA Dose Optimization Draft Guidance For Cancer Drugs Builds On OCE’s Project Optimus, Not For Gene And Cell Therapies

January 17, 2023

Prevision Policy Clips | CMS Opens National Coverage Review Of ViiV’s Apretude For PrEP

January 13, 2023

FDA Gets Granular On Dose Labeling: New Guidance On “Dosage & Administration Section” Dramatically Expands Advice And Examples From 2010 Predecessor

January 12, 2023

Medicare Price Negotiation Implementation Timeline Unveiled By CMS: “Small Biotech” Exception Is First Action Item, Overall Guidance Due By Summer

January 12, 2023

Prevision Policy Clips | FDA Updating Guidance On “Dosage & Administration” Section Of Labeling

January 12, 2023

Regeneron Eylea Pediatric Use Labeling Review: Unusual Task For FDA Advisory Committee Goes Well For VEGF-Inhibitor

January 11, 2023

Prevision Policy Clips | FDA’s Wilson Bryan To Discuss Evolution Of OTAT To Super Office At Feb. 13 Biopharma Congress

January 11, 2023

FDA Plans To Finalize OTC “Safe Use” Pathway In 2023, Updated Regulatory Agenda Says

January 11, 2023

FDA’s Very Big Year: A Guide To Legislation Enacted In 2022

January 11, 2023

FDA Chiefs Chat: Former Commissioners Debate Impact Of IRA On Drug Development, Linking Accelerated Approval To Reimbursement

January 10, 2023

Prevision Policy Clips | Missouri Rep. Jason Smith Will Chair House Ways and Means Committee

January 10, 2023

FDORA Odds And Ends: COVID Product Transition Will Be Test Case For RWE; FDA Operations Addressed Via Numerous Provisions

January 9, 2023

Highlights From UCSF-Stanford CERSI Summit: FDA’s Califf’s On Legislative “Victories,” CMS On Lecanemab Path To Coverage, Orbis for Gene Therapy?

January 9, 2023

Prevision Policy Clips | Eisai/Biogen Lecanemab (Leqembi) Clears FDA, But Medicare Coverage Will Await

January 9, 2023

FDA Advisory Committee Trends: Rejections Continue To Dominate In 2022; Will Climate For Sponsors Change In 2023?

January 6, 2023
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy